This is a routine, prearranged sale by a non-executive director and does not signal material concern. Traders should monitor for completion of these sales in upcoming Form 4 filings, but no immediate price impact is expected.
Price Chart
Executive Summary
James Mule, a director at CG Oncology, filed a Form 144 to notify intent to sell up to 17,564 shares of common stock, received through the exercise of stock options. The filing indicates planned sales under a 10b5-1 plan, with option exercises occurring as early as March 2026.
Key Facts
- James Mule, director of CG Oncology, intends to sell 17,564 shares of common stock
- Shares were or will be acquired through exercise of stock options between March 2026 and June 2025
- Sales are being conducted under a 10b5-1 plan, indicating prearranged trading strategy
- Total value of shares to be sold is approximately $116,514 based on current market price
- Filing date is April 17, 2026, with option exercises already initiated as of March 16, 2026
Financial Impact
Approximately $116,514 in shares to be sold, representing a small fraction of the company's $5.6B market cap
Risk Factors
- Potential perception of insider selling if market conditions deteriorate
- Downward pressure on stock price if sale is executed rapidly near-term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003597 |
| Document: 0001950047-26-003597-index.html | 0001950047-26-003597 |
| Document: 0001950047-26-003597.txt | 0001950047-26-003597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Aug 6, 2026 8w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Jul 27, 2026 9w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $67.38 (−7.22%) |
Jul 17, 2026 11w ago | Insider Cluster | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $67.38 (−6.22%) |
Jul 16, 2026 11w ago | Court Ruling | $69.50 $74.71 | ▲ +7.50% | ▲ +3.88% | $67.38 (−3.05%) |
Jun 24, 2026 14w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $67.38 (−7.50%) |
Jun 22, 2026 14w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $67.38 (+2.51%) |
Jun 12, 2026 16w ago | Institutional Cluster | $59.56 $75.24 | ▲ +26.33% | ▲ +24.55% | $67.38 (+13.13%) |
May 26, 2026 18w ago | 8-K | $61.89 $70.25 | ▲ +13.50% | ▲ +15.45% | $67.38 (+8.87%) |
May 15, 2026 20w ago | Press Release | $66.93 $59.56 | ▼ −11.01% | ▼ −13.13% | $67.38 (+0.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access